Search by Drug Name or NDC

    NDC 00002-2506-61 ZEPBOUND 2.5 mg/.5mL Details

    ZEPBOUND 2.5 mg/.5mL

    ZEPBOUND is a SUBCUTANEOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Eli Lilly and Company. The primary component is TIRZEPATIDE.

    Product Information

    NDC 00002-2506
    Product ID 0002-2506_dcabc03d-6a72-467a-8043-9eb12ce9c856
    Associated GPIs
    GCN Sequence Number 085488
    GCN Sequence Number Description tirzepatide PEN INJCTR 2.5 MG/0.5 SUBCUT
    HIC3 J8G
    HIC3 Description ANTI-OBESITY - INCRETIN MIMETICS COMBINATION
    GCN 54988
    HICL Sequence Number 048014
    HICL Sequence Number Description TIRZEPATIDE
    Brand/Generic Brand
    Proprietary Name ZEPBOUND
    Proprietary Name Suffix n/a
    Non-Proprietary Name tirzepatide
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION, SOLUTION
    Route SUBCUTANEOUS
    Active Ingredient Strength 2.5
    Active Ingredient Units mg/.5mL
    Substance Name TIRZEPATIDE
    Labeler Name Eli Lilly and Company
    Pharmaceutical Class G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]
    DEA Schedule n/a
    Marketing Category NDA
    Application Number NDA217806
    Listing Certified Through 2024-12-31

    Package

    NDC 00002-2506-61 (00002250661)

    NDC Package Code 0002-2506-61
    Billing NDC 00002250661
    Package 4 SYRINGE in 1 CARTON (0002-2506-61) / .5 mL in 1 SYRINGE
    Marketing Start Date 2023-11-08
    NDC Exclude Flag N
    Pricing Information N/A